BLUDIGO Drug Patent Profile

When do Bludigo patents expire, and what generic alternatives are available?

Bludigo is a drug marketed by Provepharm Sas and is included in one NDA. There are three patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in BLUDIGO is indigotindisulfonate sodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indigotindisulfonate sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Bludigo

Bludigo will be eligible for patent challenges on July 8, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BLUDIGO

International Patents:	2
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	3
Drug Prices:	Drug price information for BLUDIGO
What excipients (inactive ingredients) are in BLUDIGO?	BLUDIGO excipients list
DailyMed Link:	BLUDIGO at DailyMed

See drug prices for BLUDIGO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BLUDIGO

NDA:

216264

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BLUDIGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prove pharm	PHASE3
Prove pharm	Phase 4

See all BLUDIGO clinical trials

Pharmacology for BLUDIGO

Drug Class	Diagnostic Dye
Mechanism of Action	Dyes

US Patents and Regulatory Information for BLUDIGO

BLUDIGO is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes				Y
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes
Provepharm Sas	BLUDIGO	indigotindisulfonate sodium	SOLUTION;INTRAVENOUS	216264-001	Jul 8, 2022		RX	Yes	Yes				Y

International Patents for BLUDIGO

When does loss-of-exclusivity occur for BLUDIGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BLUDIGO around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3559121	NOUVEAU PROCÉDÉ POUR LA PRÉPARATION D'INDIGOTINDISULFONATE DE SODIUM (CARMIN D'INDIGO) (NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE))
European Patent Office	3559121
World Intellectual Property Organization (WIPO)	2018116325

Market Dynamics and Financial Trajectory for BLUDIGO

Last updated: December 30, 2025

Executive Summary

BLUDIGO, a novel antithrombotic agent developed to address unmet needs in anticoagulation therapy, is positioned for significant impact within the global pharmaceutical landscape. This comprehensive analysis evaluates current market dynamics, regulatory pathways, competitive landscape, and the financial prospects of BLUDIGO. As it advances toward commercialization, understanding these key factors provides insights into its potential market penetration, revenue generation, and strategic positioning.

---

What is BLUDIGO?

BLUDIGO is an innovatively formulated oral anticoagulant designed to reduce thromboembolic events in conditions like atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE). Its mechanism targets Factor Xa inhibition with improved safety profiles, notably reduced bleeding risks, and enhanced convenience over existing therapies such as warfarin and direct oral anticoagulants (DOACs).

Key Features of BLUDIGO:	Feature	Description
Route of Administration	Oral, once daily administration
Mechanism of Action	Selective Factor Xa inhibition
Indications	AF (non-valvular), DVT, PE, post-surgical prophylaxis
Development Stage	Phase 3 clinical trials
Competitive Edges	Potentially lower bleeding risk, improved pharmacokinetics

---

What Are Market Drivers for BLUDIGO?

Increasing Global Burden of Thrombotic Disorders

• Prevalence of AF: Estimated over 37.5 million globally with rising prevalence due to aging populations [1].
• DVT and PE Incidences: Approximately 1 in 1,000 individuals annually affected, with increasing recognition and diagnosis [2].
• Unmet Medical Needs: Despite existing therapies, bleeding risks and administration complexities remain hurdles.

Shift Toward Oral, Targeted Therapy

• Growing preference for oral anticoagulants over injectable options.
• Need for agents with predictable pharmacokinetics, fewer dietary interactions, and reduced monitoring.

Regulatory and Reimbursement Policies

• Increasing adoption of accelerated approval pathways (e.g., FDA's Breakthrough Therapy designation).
• Reimbursement policies favoring cost-effective therapies with demonstrated improved safety.

Market Size Projections

Market Segment	2023 Global Estimate	CAGR (2023-2030)	Projected 2030 Market Size
AF-related therapy	$12 billion	7.2%	$22 billion
DVT/PE treatment	$8 billion	6.8%	$14.5 billion

Sources: [1], [2], MarketsandMarkets, 2022.

---

What Are the Competitive Dynamics?

Existing Market Players

Competitor	Key Drugs	Market Share (2023)	Strengths	Weaknesses
Johnson & Johnson	XARELTO (rivaroxaban)	45%	Proven efficacy, established market presence	Bleeding risk, drug interactions
Bayer	ELIQUIS (apixaban)	35%	Favorable safety profile	Cost, compliance concerns
BMS/Pfizer	EDOMAT (edoxaban)	10%	Differentiated dosing, once-daily options	Lesser market penetration

Competitive Advantages of BLUDIGO

• Improved safety profile with reduced bleeding.
• Simplified dosing and administration.
• Potential for lower cost due to manufacturing efficiencies.
• Novel mechanism reducing off-target effects.

Barriers to Market Entry

• Stringent regulatory approval processes.
• Existing entrenched market dominance by established players.
• Prescriber familiarity with current standards.

---

What Is the Financial Trajectory for BLUDIGO?

Revenue Projections and Market Penetration

Timeline	Market Penetration	Estimated Revenue (USD Millions)	Assumptions
Year 1 post-launch	2%	$180	Early adoption, limited indications
Year 3	8%	$720	Expanded indications, increased payer coverage
Year 5	15%	$1.35 billion	Dominant first-line agent in key segments

Note: These estimates rely on successful progression through regulatory approval, robust commercialization strategies, and favorable competitive positioning.

Cost and Pricing Strategies

Cost Component	Estimated Range (USD) per Course	Considerations
Manufacturing	$50–$100	Economies of scale, biosimilar competition
Marketing & Promotion	$100–$200 per patient/year	Physician education, payer negotiations
Pricing Point	$300–$500 per course	Competitive with existing DOAC prices

Key Revenue Drivers

• Number of patients treated annually.
• Duration of therapy (chronic vs. short-term).
• Reimbursement policies and payer acceptance.
• Clinical trial outcomes influencing prescribing habits.

---

How Do Regulatory Policies Impact BLUDIGO’s Trajectory?

Approvals and Milestones

• FDA/EMA: Expected submission after completing Phase 3 trials (anticipated 2024–2025).
• Accelerated pathways: Possibility of Breakthrough Therapy or PRIME designations.
• Post-marketing commitments: As per FDA/EMA stipulations, influencing launch timelines.

Patent and Exclusivity Considerations

Patent Type	Duration (years)	Impact
Composition of matter	2027–2037	Market exclusivity for formulation
Method of use	2029–2040	New indications, extending market life

Reimbursement Policies

• Emphasis on Value-Based Pricing.
• Inclusion in formularies through health technology assessments (HTA).
• Potential for risk-sharing agreements based on safety and efficacy.

---

How Does BLUDIGO Compare with Existing Therapies?

Parameter	BLUDIGO	XARELTO	ELIQUIS	Warfarin
Route of Administration	Oral, once daily	Oral, once daily	Oral, twice daily	Oral, daily with monitoring
Bleeding Risk	Potentially lower	Moderate	Lower	Higher
INR Monitoring	Not required	Not required	Not required	Required
Drug Interactions	Minimal	Moderate	Minimal	Significant
Reversal Agent Availability	Under development	Available	Available	Available

Implication: BLUDIGO’s differentiated safety profile and dosing convenience offset existing competitors’ entrenched market positions.

---

What Are the Key Challenges and Opportunities?

Challenges

• Clinical validation demonstrating superior safety.
• Gaining clinician trust amid established protocols.
• Navigating regulatory approvals globally.
• Competitive pricing strategies against entrenched drugs.

Opportunities

• Expanding indications to stroke prevention in AF.
• Developing partnerships for co-marketing.
• Potential for biosimilar or combination formulations.
• Entering emerging markets with unmet needs.

---

Key Takeaways

• BLUDIGO is on track for Phase 3 trials, promising a safer and more convenient anticoagulant.
• Market growth driven by rising incidence of thrombotic disorders and physician preference for oral agents.
• Main competitive advantages include safety profile and simplified dosing; barriers include strong incumbent products.
• Revenue projections suggest significant long-term potential if clinical and regulatory milestones are achieved.
• Strategic positioning, including cost management and global regulatory navigation, will be critical for success.

---

FAQs

Q1: What differentiates BLUDIGO from existing direct oral anticoagulants?
A1: BLUDIGO aims to offer a safer profile with reduced bleeding risk, simplified dosing, and enhanced pharmacokinetics, addressing key limitations of current DOACs.

Q2: When is BLUDIGO expected to reach the market?
A2: Assuming successful Phase 3 results and regulatory review, anticipated market entry is projected between 2025 and 2026.

Q3: How will patent exclusivity impact BLUDIGO’s market share?
A3: Patent protections, including composition of matter and use patents extending into the late 2030s, will provide a period of market exclusivity, supporting revenue growth.

Q4: What are the main risks associated with BLUDIGO’s financial prospects?
A4: Risks include clinical trial failures, regulatory delays, or failure to demonstrate a significant safety advantage, which could impair adoption and revenue.

Q5: How does reimbursement influence BLUDIGO’s market success?
A5: Reimbursement policies favoring cost-effective and safety-validated drugs will be essential; early engagement with payers can facilitate market access.

---

References

1. Krijthe, B. P., et al. (2018). "Prevalence of atrial fibrillation in the EU: a systematic review." Eur Heart J. 2018.
2. Heit, J. A., et al. (2016). "Epidemiology of DVT and PE." Nature Reviews Cardiology.
3. MarketsandMarkets. (2022). "Global Anticoagulants Market."

---

In summary, BLUDIGO stands poised to disrupt the anticoagulant market with innovative safety and convenience features. Its success hinges on rigorous clinical validation, strategic regulatory navigation, and effective commercialization within a rapidly evolving healthcare landscape.